Vanguard Global Advisers
NPCE icon

Vanguard Global Advisers’s Neuropace NPCE Stock Holding History

Vanguard Global Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$139K Buy
10,091
+115
+1% +$1.7K ﹤0.01% 2632
2026
Q2 		$159K Hold
9,976
– – ﹤0.01% 2592
2026
Q1 		$131K Buy
+9,976
New +$150K ﹤0.01% 2613

Other funds holding NPCE

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Global Advisers's NPCE Position: Q3 2026 in Review

Vanguard Global Advisers increased its Neuropace (NPCE) stake by 1.2% in Q3 2026, buying an estimated $1.7K and bringing the position to 10,091 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Vanguard Global Advisers first reported a position in NPCE in Q1 2026 and has held it in 3 quarters since. The position peaked at $159K in Q2 2026. 68 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Vanguard Global Advisers held 10,091 shares of Neuropace worth $139K as of Q3 2026.
  • Vanguard Global Advisers bought 115 Neuropace shares in Q3 2026, an estimated $1.7K.
  • Neuropace made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2632 holding.
  • Vanguard Global Advisers first reported a position in Neuropace in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Neuropace position peaked at $159K in Q2 2026.
  • 68 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.